Efinaconazole co-crystal

Efinaconazole co-crystal
Product Description

First-in-the world oral delivery system for antifungal therapies, designed for improved, dosing and patient convenience. Global patents. S. Korea, Japan, China, US, EU, and India - covering composition, manufacturing method, sustainable production, and formulation. - Technology transfer with patent

Read more Show less

Daebong LS

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    250 - 499
Company types
Biopharmaceutical company
Drug delivery device Supplier/Manufacturer
View company profile
Categories
more categories Show less
Specifications
  • Details
    First-in-the world oral delivery system for antifungal therapies, designed for improved, dosing and patient convenience. Global patents. S. Korea, Japan, China, US, EU, and India - covering composition, manufacturing method, sustainable production, and formulation. - Technology transfer with patent
  • Model
    Technology transfer with patent
More specifications Fewer specifications

Daebong LS

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    250 - 499
Company types
Biopharmaceutical company
Drug delivery device Supplier/Manufacturer
View company profile

More Products from Daebong LS (2)

  • Azilsartan new salt

    Product Azilsartan new salt

    New salt improved drug and innovative manufacturing method. Manufacturing method of Azilsartan using eco-friendly solvents. License to implement the manufacturing method based on patents. - Technology transfer with patent
  • L-Erdosteine

    Product L-Erdosteine

    The next generation Mucolytic and Antioxidant solution. - Powerful mucolytic action. - Potent Antioxidant properties - Comprehensive therapeutic effects - An effective solution for various respiratory conditions Technology transfer with patent

Daebong LS resources (2)

  • Daebong Life Science to Showcase Innovative API Developments at CPhI Frankfurt 2025

    News Daebong Life Science to Showcase Innovative API Developments at CPhI Frankfurt 2025

    Daebong LS is pleased to announce its participation in CPhI Frankfurt 2025 on October 28th, where the company will engage in a series of B2B meetings with global partners.

    During the event, Daebong LS will highlight its latest research achievements, including:
    Efinaconazole Co-crystal
    L-Erdosteine
    Novel Salt of Azilsartan

    Through these presentations, Daebong LS aims to explore opportunities for technology transfer and strengthen collaborations with leading companies in the pharmaceutical industry.

    As an active developer of innovative active pharmaceutical ingredients (APIs), Daebong continues to expand its global partnerships and contribute to advancing healthcare solutions.

    25 Sep 2025
  • R&D Center

    Brochure R&D Center

    New R&D Center in Songdo